[Exposed] Big Pharma’s HORRIFYING New GLP-1 Scheme

Stomach paralysis.

Nausea.

Crushing fatigue.

Diarrhea.

Depression.

Millions of GLP-1 users were promised effortless weight loss and blood sugar control… but they were left with these crushing side effects instead.

And instead of fixing GLP-1s… or making them safer… it looks like Big Pharma is cooking up a VERY different scheme.

Behind the scenes, drug companies are quietly plotting to make a FORTUNE selling new meds for controlling GLP-1 side effects.

That’s right… they want to charge us for the drugs that make us sick, and then charge us again for the cure.

It’s a disgusting — and potentially dangerous — cash grab.

But, today, I’m going to reveal what’s really going on — and exactly what you need to do to stay safe.

Let me start with something that should be obvious in medicine right now, but isn’t.

No senior citizen on Earth should be taking a GLP-1.

If you’re over 65 and your doctor wants to put you on a GLP-1, here’s the single-best thing you can do to protect your health.

Get a new doctor.

These drugs eat muscle. Up to a third of the weight you lose on GLP-1s can be muscle — and mainstream medicine has tried to give the problem cute nicknames like “Ozempic butt,” as if it’s just cosmetic.

It’s not cute. And it’s not just cosmetic.

Research has repeatedly shown that your ability to preserve muscle as you age directly correlates to how long you’ll live. The more muscle you lose, the sooner you die — simple as that.

Now, of course, the drug companies aren’t going to invest a fortune in their own money to fix the problems with GLP-1s. Not when they can make a fortune off of YOUR money by trying to sell you a solution.

That’s right… there’s a drug called apitegromab that is being tested right now to help reduce the muscle loss from GLP-1s. And it could be Big Pharma’s next blockbuster.

They want to fix a problem caused by one drug… by selling you another drug. Typical Big Pharma greed.

In a clinical trial, people on GLP-1s lost an average of 7.7 pounds of muscle in six months, which is horrifying.

If I had a senior citizen in my office planning to lose nearly 8 pounds of muscle off his frame, I wouldn’t let him leave — I’d tackle him if I had to.

Anyway, once these patients added apitegromab to their treatment, they only lost about 3.5 pounds of muscle — which is still deeply concerning.

Even worse, apitegromab comes with a long list of side effects of its own, including:

• Headaches
• Fevers
• Coughs
• Upper respiratory infections
• And, of course, vomiting.

Fantastic. We already have enough people on GLP-1s feeling like they want to puke their guts out. Let’s double down on that problem, right?

But don’t worry… they’ll probably develop another drug for all of these side effects, too.

This is EXACTLY how seniors end up on 7, 8, or more medications a day.

It’s a total racket — and it up to you to keep yourself safe.

The easiest way to avoid the side effects of GLP-1s is to never take a GLP-1 to begin with. I’ve been following these meds since they hit the market, and I think they’re bad news.

The muscle loss is troubling enough… but now there are links to vision problems emerging as well.

We need to start losing weight the old-fashioned way again – by eating less and moving more. Sure it’s harder – but subjecting yourself to an endless parade of medications and side effects is no picnic, either.

In Your Corner,

Dr. Allan Spreen

In Case You Missed It

• [Breakthrough] Breast Cancer’s Worst Enemy Is Hiding In Your Trash
• [Urgent] The AI Takeover of American Medicine Is Already Here
• Lower Blood Pressure Overnight With This Kitchen Scrap
• [Warning] The Testosterone Mistake Putting MILLIONS At Risk
• [Discovered] The Strange Berry That Made Pre-Cancer DISAPPEAR
• The Knee Operation That’s WORSE Than Fake Surgery
• [Scientists Stunned] Nature’s Answer To 3 Diabetes Drugs In One

Source:

American Optometric Association. (2025, July 10). GLP-1 receptor agonists and vision risk. https://www.aoa.org/news/clinical-eye-care/public-health/glp-1-receptor-agonists-and-vision-risk

Crawford TO, Servais L, Mercuri E, et. al. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2025 Sep;24(9):727-739. doi: 10.1016/S1474-4422(25)00225-X. PMID: 40818473.

Miller, H. (2026, July 5). Worried about “Ozempic butt?” New drug could stop muscle loss tied to weight loss injections. LiveNOW from FOX. https://www.livenowfox.com/news/worried-about-ozempic-butt-new-drug-could-stop-muscle-loss-tied-weight-loss-injections